Scarica l'app Stockscreener
0.6216
2.83%
0.0171
Dopo l'orario di chiusura:
.60
-0.0216
-3.47%
Precedente Chiudi:
$0.6045
Aprire:
$0.6
Volume 24 ore:
108.00K
Relative Volume:
0.37
Capitalizzazione di mercato:
$38.39M
Reddito:
-
Utile/perdita netta:
$-76.57M
Rapporto P/E:
-0.3032
EPS:
-2.05
Flusso di cassa netto:
$-70.74M
1 W Prestazione:
-2.45%
1M Prestazione:
-4.22%
6M Prestazione:
-52.55%
1 anno Prestazione:
-5.24%
Intervallo 1D:
$0.60
$0.6457
Intervallo di 1 settimana:
$0.59
$0.6637
Portata 52W:
$0.54
$1.79
Passage Bio Inc Stock (PASG) Company Profile
Nome
Passage Bio Inc
Settore
Industria
Telefono
(267) 866-0312
Indirizzo
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-03 | Iniziato | Rodman & Renshaw | Buy |
| 2022-03-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-01-19 | Downgrade | Goldman | Buy → Neutral |
| 2021-07-01 | Iniziato | Raymond James | Outperform |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-03-04 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-02-04 | Iniziato | Guggenheim | Buy |
| 2021-01-25 | Iniziato | Wedbush | Outperform |
| 2021-01-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-12-11 | Iniziato | Citigroup | Neutral |
| 2020-08-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-25 | Downgrade | Goldman | Buy → Neutral |
| 2020-03-25 | Iniziato | Chardan Capital Markets | Buy |
| 2020-03-24 | Iniziato | Cowen | Outperform |
| 2020-03-24 | Iniziato | Goldman | Buy |
| 2020-03-24 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Passage Bio Inc Borsa (PASG) Ultime notizie
R. Nolan Townsend, Sandi See Tai, MD, and Kim G. Johnson, MD, on Gene Therapy for APOE4 Homozygous Alzheimer Disease - CGTLive™
Layoff Tracker: Marinus Cuts Employees After Disappointing Phase III Trial - BioSpace
Passage Bio reports advances in gene therapy for dementia - Investing.com
Gene therapy shows promise in frontotemporal dementia study - Investing.com
Gene therapy shows promise in frontotemporal dementia study By Investing.com - Investing.com South Africa
Passage Bio reports advances in gene therapy for dementia By Investing.com - Investing.com South Africa
Passage Bio Presents Preclinical and Interim Clinical Data - GlobeNewswire
Will Passage Bio See An Uplift? Frontotemporal Dementia Trial Data Holds The Key - RTTNews
PASG stock touches 52-week low at $0.55 amid market challenges - Investing.com
Plexxikon, Inc. - Scrip
Passage Bio Inc [PASG] 10% Owner makes an insider purchase of 39,300 shares worth 27903.0. - Knox Daily
Director Mayson Howard John sale 4,000 shares of Ovintiv Inc [OVV] - Knox Daily
Passage Bio Inc (PASG) Stock: A Year of Highs and Lows - The InvestChronicle
Passage Bio Welcomes Tom Kassberg to Board, Aiming to Strengthen Strategic Vision - MSN
Passage Bio stock hits 52-week low at $0.57 amid market challenges - Investing.com Australia
Jim Wilson’s new gene therapy company Gemma is getting up to $100M from Brazil - Head Topics
Daniela van Eickels, MD, PhD, MPH, on Bristol Myers Squibb’s Development of Cell Therapy for Autoimmune Disease - CGTLive™
Passage Bio stock hits 52-week low at $0.57 amid market challenges By Investing.com - Investing.com South Africa
Frontotemporal Dementia Pipeline 2024: Clinical Trials - openPR
Frontotemporal Dementia Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Alector, Oncolys BioPharma, Denali Therapeutics, Passage Bio - Barchart
Annovis Bio Files Patents for Innovative Therapies in Neurodegenerative Disease Treatment - MyChesCo
Passage Bio CEO to Present at H.C. Wainwright Global Investment Conference - MSN
Cabaletta Bio to Present Key Findings on CABA-201 at ACR Convergence 2024 - MyChesCo
Passage Bio’s CEO to Present at Prestigious Genetic Medicines Conference - MSN
Sage Therapeutics, Inc. (SAGE) Hits 52-Week Lows After Trial Failures, According to Short Sellers - Yahoo Finance
Market Insights: Gatos Silver Inc (GATO)’s Notable Drop of -2.63, Closing at 15.18 - The Dwinnex
NanoMosaic Transforms Cell and Gene Therapy Analytics with Advanced Quantification and Genome Mapping Capabilities. World-Renowned Expert Dr. Guangping Gao to Join Nanomosaic Scientific Advisory Board - StreetInsider.com
OrbiMed Advisors sells shares in Passage BIO worth over $27k - Investing.com India
CASI Pharmaceuticals (NASDAQ:CASI) Shares Pass Above Two Hundred Day Moving Average of $4.60 - Defense World
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference - ForexTV.com
Mercer Global Advisors Inc. ADV Acquires 10,658 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Passage Bio Shares Promising Data on PBFT02 for Frontotemporal Dementia - MSN
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc - Yahoo Finance
OrbiMed Advisors sells shares of Passage Bio worth over $146,000 - Investing.com
OrbiMed Advisors sells shares of Passage Bio worth over $146,000 By Investing.com - Investing.com UK
Canaccord sees Passage Bio stock potential in positive Phase 1/2 trial data - Investing.com
PASG’s 52-Week Rollercoaster: From $0.58 to $1.79 – What’s Next for Investors? - The InvestChronicle
Financial Metrics Unveiled: Passage Bio Inc (PASG)’s Key Ratios in the Spotlight - The Dwinnex
Passage Bio Reveals Promising Gene Therapy Trial Results - TipRanks
Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024) - StockTitan
Passage Bio to Present Positive Interim Data from Cohort 1 - GlobeNewswire
Cornercap Investment Counsel Inc. Has $5.64 Million Stake in Meta Platforms, Inc. (NASDAQ:META) - Defense World
Passage Bio Inc Azioni (PASG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Passage Bio Inc Azioni (PASG) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% Owner |
Sep 17 '24 |
Sale |
0.73 |
111,400 |
81,322 |
7,859,500 |
| ORBIMED ADVISORS LLC | 10% Owner |
Sep 16 '24 |
Sale |
0.74 |
63,100 |
46,694 |
7,970,900 |
| ORBIMED ADVISORS LLC | 10% Owner |
Sep 18 '24 |
Sale |
0.73 |
25,631 |
18,711 |
7,833,869 |
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):